Literature DB >> 10996031

Differential effects of pentoxifylline, a non-specific phosphodiesterase inhibitor, on the production of IL-10, IL-12 p40 and p35 subunits by murine peritoneal macrophages.

J Marcinkiewicz1, A Grabowska, R Lauterbach, M Bobek.   

Abstract

Pentoxifylline (PTX), a methylxanthine derivative, has been reported to be an effective drug in inhibiting TNF-alpha responses during septic shock. The inhibition of TNF-alpha production seems to be correlated with increased intracellular cAMP levels. PTX also affects the production of other cytokines such as IL-1, IL-6, IL-10, IL-12, and IFN-gamma. However, inhibition, as well as enhancement of cytokine production, has been observed in vitro, depending on the PTX concentration and cell type used.IL-12 is a heterodimeric cytokine that plays an important role in the development of Th1-mediated inflammatory responses. IL-12 along with TNF-alpha and other proinflammatory cytokines has shown to be responsible for the pathological reaction, which may lead to septic shock. For biological activity, the expression of both subunits of IL-12, p35 and p40, is required. Moreover, the p40 chain of IL-12 specifically inhibits the effects of the IL-12 heterodimer. In this study, we investigated the effects of PTX on the production of both proinflammatory (TNF-alpha, IL-6, IL-12) and anti-inflammatory (IL-10) cytokines by murine macrophages (Mφ). We have found that PTX, at concentrations below 100 microg/ml, selectively inhibited the production of TNF-alpha. Forskolin, a cAMP-elevating agent, similarly affected the production of the cytokines tested. However, at higher concentrations, PTX inhibited the production of TNF-alpha, IL-10, and IL-12 p35, but surprisingly, PTX enhanced the production of IL-12 p40. Concentrations of IL-10 were negatively correlated with the concentrations of IL-12 p40 subunit. These results further confirm the relevance of the use of PTX in clinical trials of immunological disorders characterised by inappropriate Th1 type immune responses.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10996031     DOI: 10.1016/s0162-3109(00)00249-6

Source DB:  PubMed          Journal:  Immunopharmacology        ISSN: 0162-3109


  16 in total

1.  Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines.

Authors:  Mona E E Elfaki; Eltahir A G Khalil; Anne S De Groot; Ahmed M Musa; Andres Gutierrez; Brima M Younis; Kawthar A M Salih; Ahmed M El-Hassan
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

2.  Evaluation of the protective effect of pentoxifylline on carrageenan-induced chronic non-bacterial prostatitis in rats.

Authors:  Mahboobeh Hajighorbani; Mahmood Ahmadi-Hamedani; Elaheh Shahab; Farzad Hayati; Khatereh Kafshdoozan; Keivan Keramati; Amin Hossein Amini
Journal:  Inflammopharmacology       Date:  2017-03-09       Impact factor: 4.473

3.  Pentoxifylline modulates LPS-induced hyperinflammation in monocytes of preterm infants in vitro.

Authors:  Simone S Schüller; Lukas Wisgrill; Elisabeth Herndl; Andreas Spittler; Elisabeth Förster-Waldl; Kambis Sadeghi; Boris W Kramer; Angelika Berger
Journal:  Pediatr Res       Date:  2017-05-24       Impact factor: 3.756

4.  Pentoxifylline alleviates vascular impairment in insulin resistance via TNF-α inhibition.

Authors:  Hany M El-Bassossy; Mohamed A El-Moselhy; Mona F Mahmoud
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-07-29       Impact factor: 3.000

5.  Antinociceptive, anti-inflammatory and antipyretic activities of the leaf methanol extract of Ruta graveolens L. (Rutaceae) in mice and rats.

Authors:  Firdows Loonat; George Jimboyeka Amabeoku
Journal:  Afr J Tradit Complement Altern Med       Date:  2014-04-03

6.  Pentoxifylline inhibits the synthesis and IFN-gamma-inducing activity of IL-18.

Authors:  T Samardzic; V Jankovic; S Stosic-Grujicic; D Popadic; V Trajkovic
Journal:  Clin Exp Immunol       Date:  2001-05       Impact factor: 4.330

7.  Design and rationale of a multicenter defeat alcoholic steatohepatitis trial: (DASH) randomized clinical trial to treat alcohol-associated hepatitis.

Authors:  Srinivasan Dasarathy; Mack C Mitchell; Bruce Barton; Craig J McClain; Gyongyi Szabo; Laura E Nagy; Svetlana Radaeva; Arthur J McCullough
Journal:  Contemp Clin Trials       Date:  2020-07-31       Impact factor: 2.226

Review 8.  Immunological mechanisms of pentoxifylline in chronic heart failure.

Authors:  Steven M Shaw; Mohammed K H Shah; Simon G Williams; James E Fildes
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

9.  A randomized double-blinded placebo-controlled clinical trial on protective effects of pentoxifylline on gentamicin nephrotoxicity in infectious patients.

Authors:  Seyed Ruhollah Mousavinasab; Zohreh Akhoundi-Meybodi; Laleh Mahmoudi; Iman Karimzadeh
Journal:  Clin Exp Nephrol       Date:  2021-04-01       Impact factor: 2.801

10.  Structure-based redesigning of pentoxifylline analogs against selective phosphodiesterases to modulate sperm functional competence for assisted reproductive technologies.

Authors:  Mutyala Satish; Sandhya Kumari; Waghela Deeksha; Suman Abhishek; Kulhar Nitin; Satish Kumar Adiga; Padmaraj Hegde; Jagadeesh Prasad Dasappa; Guruprasad Kalthur; Eerappa Rajakumara
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.